

Next-Generation Immunology Drugs Market Size, Share and Growth Outlook 2026: By Drug Class, By Therapeutic Area, By Technology, By Route of Administration, By End-User, Companies to 2034

<https://marketpublishers.com/r/NE3B79047056EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: NE3B79047056EN

Abstracts

The global Next-Generation Immunology Drugs Market size is forecast to increase from \$56.2 Billion in 2026 to \$101.66 Billion in 2034 at a CAGR of 7.69% between 2026 and 2034.

The Next-Generation Immunology Drugs market report provides detailed analysis and outlook of Next-Generation Immunology Drugs segments including By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, Immune Checkpoint Inhibitors, Fusion Proteins, Cytokines, Small Molecules, Cell-Based Therapies), By Therapeutic Area (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases), By Technology (Cell Therapy Platforms, Antibody Engineering Platforms, Gene Therapy Platforms), By Route of Administration (Intravenous, Parenteral, Intratumoral, Oral), By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Next-Generation Immunology Drugs Industry Overview

Precision Immunology and Targeted Biologics Are Transforming Autoimmune Disease Treatment

The next-generation immunology drugs industry is experiencing rapid advancement as pharmaceutical companies develop highly targeted therapies designed to modulate

specific immune pathways involved in chronic inflammatory and autoimmune disorders. Advances in cytokine biology, monoclonal antibody engineering, immune signaling pathways, and precision medicine are enabling the development of treatments that deliver improved efficacy while reducing reliance on broad immunosuppressive approaches. The industry is expanding across dermatology, allergy, rare diseases, autoimmune disorders, and inflammatory conditions, with growing emphasis on long-term disease control, steroid-sparing regimens, and personalized treatment strategies. Regulatory approvals and expanding clinical evidence are accelerating adoption of innovative biologics and immune-targeted therapies worldwide.

Long-Term Clinical Evidence Strengthens Confidence in Advanced Immunology Therapies

A defining trend within the industry is the growing availability of long-duration safety and efficacy data supporting chronic treatment use. AbbVie reported six-year findings from its extensive Phase 3 clinical program evaluating upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis. Covering more than 9,000 patient-years of exposure, the data demonstrated stable safety outcomes with low rates of major adverse cardiovascular events and no evidence of cumulative toxicity. These results provide important support for long-term maintenance strategies utilizing selective JAK1 inhibition and reinforce the growing role of oral targeted therapies in chronic immune-mediated diseases. As physicians increasingly seek durable treatment options, extended clinical follow-up data is becoming a key differentiator across competitive immunology markets.

Novel Immune Pathway Targets Expand Therapeutic Opportunities

Innovation within the sector continues to expand through therapies targeting previously underserved disease pathways. Sanofi and Regeneron secured FDA approval for Dupixent® in bullous pemphigoid, making it the first targeted biologic approved for this autoimmune blistering disorder. The approval was supported by Phase 2/3 data demonstrating significantly higher corticosteroid-free remission rates through inhibition of IL-4 and IL-13 signaling pathways. Meanwhile, CSL expanded commercialization of Andembry® (garadacimab), a first-in-class monoclonal antibody targeting activated Factor XIIa for hereditary angioedema prevention. Clinical evidence from the VANGUARD program demonstrated substantial reductions in inflammatory attack frequency with convenient once-monthly administration. These developments highlight the industry's shift toward highly selective immune pathway modulation, expansion into rare diseases, and development of next-generation biologics capable of delivering

durable clinical benefits across complex immunological disorders.

Next-Generation Immunology Drugs Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Next-Generation Immunology Drugs market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Merck & Co., Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca, Pfizer Inc., Novartis AG, Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company. The Next-Generation Immunology Drugs market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Next-Generation Immunology Drugs industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Next-Generation Immunology Drugs Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Next-Generation Immunology Drugs companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Next-Generation Immunology Drugs markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Next-Generation Immunology Drugs Market Competitive Benchmarking and Company Analysis

Leading companies in Next-Generation Immunology Drugs industry include- Merck & Co., Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca, Pfizer Inc., Novartis AG, Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company. The Next-Generation Immunology Drugs market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Next-Generation Immunology Drugs Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Next-Generation Immunology Drugs market remains one of the strongest-performing segments in the country.

The US Next-Generation Immunology Drugs Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Next-Generation Immunology Drugs market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Next-Generation Immunology Drugs industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Next-Generation Immunology Drugs markets

Canada's strong Next-Generation Immunology Drugs sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Next-Generation Immunology Drugs market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Next-Generation Immunology Drugs Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Next-Generation Immunology Drugs market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Next-Generation Immunology Drugs population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Next-Generation Immunology Drugs industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Next-Generation Immunology Drugs market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Next-Generation Immunology Drugs sales through 2034

France Next-Generation Immunology Drugs companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to

improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Next-Generation Immunology Drugs Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Next-Generation Immunology Drugs distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Next-Generation Immunology Drugs Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Next-Generation Immunology Drugs market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Next-Generation Immunology Drugs industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more

pronounced in the Chinese Next-Generation Immunology Drugs industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Next-Generation Immunology Drugs Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Next-Generation Immunology Drugs market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Next-Generation Immunology Drugs market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Next-Generation Immunology Drugs Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria,

and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Next-Generation Immunology Drugs Market Segmentation

By Drug Class

Monoclonal Antibodies

Antibody-Drug Conjugates

Immune Checkpoint Inhibitors

Fusion Proteins

Cytokines

Small Molecules

Cell-Based Therapies

By Therapeutic Area

Cancer

Autoimmune Diseases

Infectious Diseases

Inflammatory Diseases

By Technology

Cell Therapy Platforms

Antibody Engineering Platforms

Gene Therapy Platforms

By Route of Administration

Intravenous

Parenteral

Intratumoral

Oral

By End-User

Hospitals

Specialty Clinics

Academic and Research Institutes

Leading Companies in Next-Generation Immunology Drugs Industry (2026)

Merck & Co., Inc.

Johnson & Johnson

F. Hoffmann-La Roche Ltd.

AbbVie Inc.

AstraZeneca

Pfizer Inc.

Novartis AG

Amgen Inc.

Bristol Myers Squibb

Eli Lilly and Company

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Next-Generation Immunology Drugs Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Next-Generation Immunology Drugs Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL NEXT-GENERATION IMMUNOLOGY DRUGS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Next-Generation Immunology Drugs Markets in 2026
- 3.2. Global Historic and Forecast Next-Generation Immunology Drugs Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics

- 3.4.1. Key Next-Generation Immunology Drugs Market Driving Forces and Their Impact on Market Outlook
- 3.4.2. Short and Long-Term Trends and Insights Shaping the Future
- 3.4.3. Potential Next-Generation Immunology Drugs Market Opportunities for Industry Stakeholders
- 3.4.4. Potential Challenges across Next-Generation Immunology Drugs Value Chain

CHAPTER 4- NEXT-GENERATION IMMUNOLOGY DRUGS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

- 4.1. Porter's Five Forces Analysis
 - 4.1.1. Bargaining Power of Buyers
 - 4.1.2. Bargaining Power of Suppliers
 - 4.1.3. Threat of Substitutes
 - 4.1.4. Threat of New Entrants
 - 4.1.5. Intensity of Competitive Rivalry
 - 4.1.6. Market Attractiveness Analysis by Segment
 - 4.1.7. Market Attractiveness Analysis by Region
- 4.2. Competitive Landscape
 - 4.2.1 Market Share Analysis of Leading Next-Generation Immunology Drugs Companies
 - 4.2.2 Recent Strategic Developments
 - 4.2.3 Mergers, Acquisitions, and Partnerships
 - 4.2.4 Product Launches and Innovation Trends
 - 4.2.5 Key Success Factors
- 4.3. Value Chain Analysis
 - 4.3.1. Key Value Chain Segments
 - 4.3.2. Dominant players by value-chain stage
- 4.4. SWOT Analysis
 - 4.4.1. Key Strengths and Opportunities
 - 4.4.2. Major Weaknesses and Threats
- 4.5 Technology Roadmap
- 4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- NEXT-GENERATION IMMUNOLOGY DRUGS MARKET OUTLOOK BY SEGMENTS

- 5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
- 5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Drug Class

Monoclonal Antibodies

Antibody-Drug Conjugates

Immune Checkpoint Inhibitors

Fusion Proteins

Cytokines

Small Molecules

Cell-Based Therapies

By Therapeutic Area

Cancer

Autoimmune Diseases

Infectious Diseases

Inflammatory Diseases

By Technology

Cell Therapy Platforms

Antibody Engineering Platforms

Gene Therapy Platforms

By Route of Administration

Intravenous

Parenteral

Intratumoral

Oral

By End-User

Hospitals

Specialty Clinics

Academic and Research Institutes

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario

6.1.1. Definitions and Insights

6.1.2. Market Size Outlook to 2034

6.2. Low Growth Case Scenario

6.2.1. Definitions and Insights

6.2.2. Market Size Outlook to 2034

6.3. High Growth Case Scenario

6.3.1. Definitions and Insights

6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA NEXT-GENERATION IMMUNOLOGY DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Next-Generation Immunology Drugs Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Next-Generation Immunology Drugs Market Trends and Growth Opportunities to 2034
- 7.5. North America Next-Generation Immunology Drugs Market Size Outlook by Type
- 7.6. North America Next-Generation Immunology Drugs Market Size Outlook by Application
- 7.7. North America Next-Generation Immunology Drugs Market Size Outlook by Country
- 7.8. United States
 - 7.8.1. Key Statistics
 - 7.8.2. The US Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 7.8.3. Key Market Drivers and Industry Developments in the US Next-Generation Immunology Drugs Companies
- 7.9. Canada
 - 7.9.1. Key Statistics
 - 7.9.2. Canada Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 7.9.3. Key Market Drivers and Industry Developments in Canada Next-Generation Immunology Drugs Companies
- 7.10. Mexico
 - 7.10.1. Key Statistics
 - 7.10.2. Mexico Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 7.10.3. Key Market Drivers and Industry Developments in Mexico Next-Generation Immunology Drugs Companies

CHAPTER 8- EUROPE NEXT-GENERATION IMMUNOLOGY DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

- 8.1. Europe Next-Generation Immunology Drugs Market Overview, 2026
- 8.2. Leading Companies Operating in Europe
- 8.3. Key Industry Statistics, 2026
- 8.4. Europe Next-Generation Immunology Drugs Market Trends and Growth Opportunities to 2034
- 8.5. Europe Next-Generation Immunology Drugs Market Size Outlook by Type

8.6. Europe Next-Generation Immunology Drugs Market Size Outlook by Application

8.7. Europe Next-Generation Immunology Drugs Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Next-Generation Immunology Drugs Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Next-Generation Immunology Drugs Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Next-Generation Immunology Drugs Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Next-Generation Immunology Drugs Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Next-Generation Immunology Drugs Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Next-Generation Immunology Drugs Companies

CHAPTER 9- ASIA PACIFIC NEXT-GENERATION IMMUNOLOGY DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Next-Generation Immunology Drugs Market Overview, 2026

- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Next-Generation Immunology Drugs Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Next-Generation Immunology Drugs Market Size Outlook by Type
- 9.6. Asia Pacific Next-Generation Immunology Drugs Market Size Outlook by Application
- 9.7. Asia Pacific Next-Generation Immunology Drugs Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Next-Generation Immunology Drugs Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 9.9.3. Key Market Drivers and Industry Developments in Japan Next-Generation Immunology Drugs Companies
- 9.10. India
 - 9.10.1. Key Statistics
 - 9.10.2. India Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 9.10.3. Key Market Drivers and Industry Developments in India Next-Generation Immunology Drugs Companies
- 9.11. South Korea
 - 9.11.1. Key Statistics
 - 9.11.2. South Korea Next-Generation Immunology Drugs Market Size Outlook, 2021-2034
 - 9.11.3. Key Market Drivers and Industry Developments in South Korea Next-Generation Immunology Drugs Companies
- 9.12. Australia
 - 9.12.1. Key Statistics
 - 9.12.2. Australia Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 9.12.3. Key Market Drivers and Industry Developments in Australia Next-Generation Immunology Drugs Companies
- 9.13. Southeast Asia
 - 9.13.1. Key Statistics
 - 9.13.2. Southeast Asia Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034
 - 9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Next-

Generation Immunology Drugs Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA NEXT-GENERATION IMMUNOLOGY DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Next-Generation Immunology Drugs Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Next-Generation Immunology Drugs Market Trends and Growth Opportunities to 2034

10.5. South and Central America Next-Generation Immunology Drugs Market Size Outlook by Type

10.6. South and Central America Next-Generation Immunology Drugs Market Size Outlook by Application

10.7. South and Central America Next-Generation Immunology Drugs Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Next-Generation Immunology Drugs Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Next-Generation Immunology Drugs Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Next-Generation Immunology Drugs Companies

CHAPTER 11- MIDDLE EAST AND AFRICA NEXT-GENERATION IMMUNOLOGY DRUGS MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Next-Generation Immunology Drugs Market Overview,

2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Next-Generation Immunology Drugs Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Next-Generation Immunology Drugs Market Size Outlook by Type

11.6. Middle East and Africa Next-Generation Immunology Drugs Market Size Outlook by Application

11.7. Middle East and Africa Next-Generation Immunology Drugs Market Size Outlook by Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Next-Generation Immunology Drugs Market Size Outlook, 2021-2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Next-Generation Immunology Drugs Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Next-Generation Immunology Drugs Market Size Outlook, 2021-2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Next-Generation Immunology Drugs Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Next-Generation Immunology Drugs Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Next-Generation Immunology Drugs Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Next-Generation Immunology Drugs Industry

Merck & Co., Inc.

Johnson & Johnson

F. Hoffmann-La Roche Ltd.

AbbVie Inc.

AstraZeneca

Pfizer Inc.

Novartis AG

Amgen Inc.
Bristol Myers Squibb
Eli Lilly and Company
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations

I would like to order

Product name: Next-Generation Immunology Drugs Market Size, Share and Growth Outlook 2026: By Drug Class, By Therapeutic Area, By Technology, By Route of Administration, By End-User, Companies to 2034

Product link: <https://marketpublishers.com/r/NE3B79047056EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE3B79047056EN.html>